Abstract
The first trial of nivolumab as a first-line therapy for non-small cell lung cancer suggests that the drug can improve survival. Adding some platinum-doublet chemotherapy combinations did not further increase this effect, although the median overall survival wasn't reached for paclitaxel and carboplatin. Adding chemotherapy may increase the immunotherapy's toxicity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
